As of May 28, 2025, Nymox Pharmaceutical Corp (NYMX) reports a Net Margin of -117400.00%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Nymox Pharmaceutical Corp's Net Margin
Over recent years, Nymox Pharmaceutical Corp's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -117400.00% |
| 2021-12-31 | -117400.00% |
| 2020-12-31 | -10966.67% |
| 2019-12-31 | -3530.00% |
| 2018-12-31 | -6104.55% |
This gradual decrease highlights how Nymox Pharmaceutical Corp manages its overall profitability and cost control over time.
Comparing Nymox Pharmaceutical Corp's Net Margin to Peers
To better understand Nymox Pharmaceutical Corp's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Nymox Pharmaceutical Corp (NYMX) | -117400.00% |
| Aptose Biosciences Inc (APS.TO) | 4175.00% |
| Fennec Pharmaceuticals Inc (FENC) | -0.92% |
| Theratechnologies Inc (TH.TO) | -9.67% |
| Protara Therapeutics Inc (TARA) | -113.22% |
| Repare Therapeutics Inc (RPTX) | -158.37% |
Compared to its competitors, Nymox Pharmaceutical Corp's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.